A Randomized Controlled Pharmacist Intervention Study to Reduce Drug-related Problems and Readmissions Among Old People With Dementia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hugo Lovheim, Umeå University
ClinicalTrials.gov Identifier:
NCT01504672
First received: January 3, 2012
Last updated: November 30, 2015
Last verified: November 2015

January 3, 2012
November 30, 2015
January 2012
June 2015   (final data collection date for primary outcome measure)
Frequency of drug related readmissions [ Time Frame: Six months follow-up ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01504672 on ClinicalTrials.gov Archive Site
  • Cost for visits for readmissions and to the Emergency Department compared between patients in the control group and intervention group. [ Time Frame: Six months follow-up ] [ Designated as safety issue: No ]
  • Time until institutionalization after discharge compared between control group and intervention group. [ Time Frame: Six months follow-up ] [ Designated as safety issue: No ]
  • Frequency of hospital visits (readmissions and emergency department) during the 6-month follow-up. [ Time Frame: Six months follow-up ] [ Designated as safety issue: No ]
  • Time from discharge to readmission [ Time Frame: Six months follow-up ] [ Designated as safety issue: No ]
  • Adherence to the quality indicators published by the Swedish National Board of Health and Welfare [ Time Frame: Six months follow-up ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Randomized Controlled Pharmacist Intervention Study to Reduce Drug-related Problems and Readmissions Among Old People With Dementia
A Randomized Controlled Pharmacist Intervention Study to Reduce Drug-related Problems and Readmissions Among Old People With Dementia

The aim of this randomized controlled study is to investigate if medication reviews performed by a clinical pharmacist as part of a ward team can reduce drug related problems and reduce readmissions to hospital among elderly patients (≥65 years) with dementia and cognitive failure.

Four hundred and sixty patients will be recruited and randomized to control (usual care) and intervention group (enhanced service in which a pharmacist is part of the health care team).

Six months after the last patient of the 460 has been discharged the study will be closed. Data about the number of readmissions and visits to the emergency room will be collected during the six-month follow-up and also, the costs associated with each visit or admission. Time until institutionalization will be compared between intervention group and control group.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Cognitive Impairment
Other: Medication review

In the intervention, the pharmacist will evaluate:

  • Is there an indication for the drug?
  • Has the drug desired effect?
  • Is the dose correct and dosing scheme correct?
  • Side effects, contraindications, inappropriate drugs
  • Interactions
  • Treatment time
  • Cost effectiveness
  • Adherence to recommendation list
  • Problems with handling the drugs (for example crushing of the tablets)
  • Untreated indication
  • Double medications
  • Administration of drugs
  • Experimental: Medication review
    Intervention: Other: Medication review
  • No Intervention: Usual care
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
460
August 2015
June 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with dementia or cognitive impairment
  • Patients ≥ 65 years

Exclusion Criteria:

  • Patients previously admitted to the study wards during the study period
Both
65 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Sweden
 
NCT01504672
UmU-2011-148-31M
Not Provided
Not Provided
Not Provided
Hugo Lovheim, Umeå University
Umeå University
Not Provided
Principal Investigator: Hugo Lövheim, MD, PhD Umeå University, Umeå, Sweden
Umeå University
November 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP